Vestnik Dermatologii i Venerologii (Aug 2017)
Efficacy and cosmetic properties of drug forms of hydrocortisone 17-butyrate for patients with allergic contact dermatitis: a prospective observational program
Abstract
Objective. To assess the duration of the therapy needed for complete eradication of clinical manifestations of allergic contact dermatitis (ACD) and evaluate how patients perceive cosmetic properties of Locoid, and to assess etiological factors of ACD based on the medical history. Materials and methods. The authors performed an open multicenter prospective observational program of observations of ACD patients receiving treatment with Locoid (in the form of Lipocream or Crelo). As many as 149 patients were involved. The patients received treatment with Locoid according to the routine practice until complete eradication of the lesions but for not more than 30 days. Prior to the onset of treatment, the etiological factor that caused ACD was evaluated. Upon the completion of the therapy, patients completed questionnaire forms to assess the cosmetic properties of the drug. Results. The authors demonstrated high clinical efficacy of the drug: ACD symptoms were eradicated in 96.64% of the patients; the median treatment duration amounted to 7 days. Cosmetic properties of the drug and general satisfaction with treatment were high regardless of the drug form (Lipocream or Crelo). In the sample under observation, the use of different cosmetic products was the most frequent reason of ACD. High safety of Locoid was demonstrated: adverse events were observed in one patient only. Conclusion. The duration of the therapy needed for complete eradication of clinical manifestations of allergic contact dermatitis is 7 days (median: quartiles of 5-9 days). The perception of cosmetic properties of both Locoid drug forms (Lipocream or Crelo) is positive; general satisfaction with treatment is high and does not depend on the drug form.
Keywords
